Evidence map›Paper›PMID 40878953›Full record

ArticleEuropean journal of immunology2025

Signal Transducer and Activator of Transcription 3 (STAT3) Variant p.K709N Causes Hyper-IgE Syndrome Likely by Impaired STAT3-Dimer Formation.

Beate Hagl, Benedikt D Spielberger, Betina Neumann, Simon J Pelham, Dharmendra Pandey, Andreas Schlundt, Camille Barro, Anica Lechner, Christine Wolf, Elissa K Deenick and 4 more

Abstract readCase Reports
In one paragraph

Article in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Beate HaglTranslational Immunology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.ORCID 0000-0002-0717-3508
Benedikt D SpielbergerTranslational Immunology in Environmental Medicine, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Betina NeumannTranslational Immunology in Environmental Medicine, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Simon J PelhamGarvan Institute of Medical Research, Sydney, Australia.
Dharmendra PandeyDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.
Andreas SchlundtTUM School of Natural Sciences, Bavarian NMR Center and Department of Bioscience, Technical University of Munich, Garching, Germany.
Camille BarroDepartment of Pediatrics, TUM University Hospital, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Anica LechnerTranslational Immunology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Christine WolfTranslational Immunology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Elissa K DeenickGarvan Institute of Medical Research, Sydney, Australia.
Michael SattlerTUM School of Natural Sciences, Bavarian NMR Center and Department of Bioscience, Technical University of Munich, Garching, Germany.
Stuart G TangyeGarvan Institute of Medical Research, Sydney, Australia.
Simon RothenfusserDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.
Ellen D RennerTranslational Immunology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.ORCID 0000-0001-9816-8538

Funding

Deutsche Forschungsgemeinschaft 404450088Deutsche Forschungsgemeinschaft RE2799/3-1Deutsche Forschungsgemeinschaft Ro 25257/-1 grant number 391217598Deutsche Forschungsgemeinschaft SFB/TR-237-B14 grant number 369799452 - projectEuropean Union 101137459European Union Yellow4Flavi-projectFritz Bender StiftungHelmholtz Association Helmholtz Translational Clinical ProjectHelmholtz-Future topic "Immunology and Inflammation"Job Research FoundationNational Health and Medical Research Council NHMRC Leadership 3 Investigator Grant (1176665)National Health and Medical Research Council Principal Research Fellow (1042925)National Health and Medical Research Council program grant (1113904)Wilhelm Sander-Stiftung 2013.015.2Wilhelm Sander-Stiftung 2021.156.1
6 · The paper itself

Abstract

STAT3-hyper-IgE syndrome (STAT3-HIES) is an inborn error of immunity caused by heterozygous dominant-negative mutations in the signal transducer and activator of transcription 3 (STAT3). In this study, we evaluate the functional relevance of a previously undescribed heterozygous STAT3 variant in a patient with clinical findings of STAT3-HIES. Flow cytometry, quantitative real-time PCR, pull-down assays, native PAGE, DNA-binding ELISA, and 3D-structural data analysis were performed. Genetic analysis identified the heterozygous STAT3 variant NM_139276.2:c.2127G>C (NP_644805.1:p.(K709N); short: p.K709N) in a patient with a clinical and laboratory phenotype characteristic of STAT3-HIES, including early onset severe eczema, chronic lung disease, eosinophilia, and elevated serum IgE levels. While STAT3 p.K709N did not significantly affect STAT3 phosphorylation, STAT3 target gene expression was impaired in patient cells. Expression of STAT3 p.K709N and wild-type STAT3 in STAT3-deficient cells indicated a dominant-negative effect by the mutation. Analysis of 3D-structural data and modeling suggested a central role of the affected amino acid K709 in stabilizing a C-terminal loop in STAT3 essential for dimer formation. Consequently, p.K709N resulted in diminished STAT3 dimerization and reduced DNA binding in patient cells. Functional analyses verified STAT3 p.K709N to cause STAT3-HIES and suggest that STAT3 p.K709N impairs STAT3 dimer formation.

Indexed as

Job SyndromeSTAT3 Transcription FactorAdultFemaleHumansImmunoglobulin EMutationPhosphorylationProtein MultimerizationImmunoglobulin ESTAT3 protein, humanSTAT3 Transcription FactordimerizationHIESHyper‐IgE syndromeSTAT3variant classification

Identifiers

PMID40878953
PMCPMC12304596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.